Study of Immunotherapy Combinations for Patients with HER2-Positive Metastatic Breast Cancer

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

Breast Cancer Breakout: Rapid research developments and new treatment combinationsПодробнее

Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancerПодробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

2023 Updates In Metastatic Breast Cancer TreatmentПодробнее

HER2 In Breast Cancer: Testing Guidelines and New Treatment ApproachesПодробнее

Study comparing margetuximab combinations to trastuzumab combinations in HER2-positive breast cancerПодробнее

Breast Cancer and Immunotherapy with Dr. Leisha Emens and Barbara BigelowПодробнее

Therapeutic landscape for patients with HER2-positive breast cancer with active brain metastasesПодробнее

Research Update for HER2-Positive MBC | 2021-2022 EMBRACE MBC Virtual Forum SeriesПодробнее

Dr. Khong on Endocrine Combinations in ER+/HER2- Breast CancerПодробнее

WeOncologists ESO Presents:"Current Landscape in HER2+ metastatic Breast Cancer” by Philippe AftimosПодробнее

INB03 and Lapatinib Reverses Resistance to Trastuzumab in HER2+ Breat Cancer in Pre-clinical Models.Подробнее

Advances in HER2-positive and HER2-low Breast CancerПодробнее

Breast Cancer Immunotherapy with Dr. Sylvia Adams and Victor Ty, BSN, RNПодробнее

Tucatinib Combination Improved Survival in HER2–Positive Breast CancerПодробнее

HER2 Positive Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019Подробнее

Breast Cancer and the Immune System at MBC Patient Forum 2019Подробнее

Combination Immunotherapy Appears Promising in Breast Cancer SubtypesПодробнее

2021 West Oncology | Breast Cancer | Update on Brain MetastasesПодробнее